To include your compound in the COVID-19 Resource Center, submit it here.

Immuno-oncology play Arcus raises $107M

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV.

New investors Wellington Management,

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE